The Year in Cardiac Imaging

Division of Cardiovascular Diseases and Internal Medicine, Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Journal of the American College of Cardiology (Impact Factor: 16.5). 04/2011; 57(17):1721-34. DOI: 10.1016/j.jacc.2011.01.018
Source: PubMed


This review is a sequel to our 3 previous reports highlighting the most important recent literature in single-photon emission computed tomography (SPECT), myocardial perfusion imaging, cardiac positron emission tomography (PET), cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI). In contrast to our previous reports, which covered 1 year each, this report covers the English-language literature over a 15-month period from April 1, 2007, to June 30, 2008. The increased length of our coverage period has magnified the difficulty of reaching a decision as to which articles merit inclusion. Our previous decisions have pleased some authors and disappointed others. We have again made every effort to avoid our personal biases in reaching these ever more difficult decisions. Our summary is once again organized around topical themes, reflecting the growing interest in integrated, multimodality imaging to solve clinical problems.

Download full-text


Available from: Eric E Williamson, Mar 20, 2015
21 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: {{Objective: To determine the prognostic and therapeutic implications of stress perfusion cardiovascular magnetic resonance (CMR) on the basis of the ischaemic cascade. Setting: Single centre study in a teaching hospital in Spain. Patients: Dipyridamole stress CMR was performed on 601 patients with ischaemic chest pain and known or suspected coronary artery disease. On the basis of the ischaemic cascade, patients were categorised in C1 (no evidence of ischaemia
  • Journal of Nuclear Cardiology 08/1997; 7(5):545. DOI:10.1016/S1071-3581(97)90114-8 · 2.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Activation of the coagulation cascade is commonly observed in the lungs of patients with both acute and chronic inflammatory and fibrotic lung disorders, as well as in animal models of these disorders. The aim of this study was to examine the contribution of the major thrombin receptor, proteinase-activated receptor-1 (PAR-1), during the acute inflammatory and chronic fibrotic phases of lung injury induced by intratracheal instillation of bleomycin in mice. Inflammatory cell recruitment and increases in bronchoalveolar lavage fluid (BALF) protein were attenuated by 56 +/- 10% (P < 0.05) and 53 +/- 12% (P < 0.05), respectively, in PAR-1-deficient (PAR-1-/-) mice compared with wild-type (WT) mice. PAR-1-/- mice were also protected from bleomycin-induced pulmonary fibrosis with total lung collagen accumulation reduced by 59 +/- 5% (P < 0.05). The protection afforded by PAR-1 deficiency was accompanied by significant reductions in pulmonary levels of the potent PAR-1-inducible proinflammatory and profibrotic mediators, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor-beta-1 (TGF-beta1), and connective tissue growth factor/fibroblast-inducible secreted protein-12 (CTGF/FISP12). In addition, PAR-1 was highly expressed in inflammatory and fibroproliferative lesions in lung sections obtained from patients with fibrotic lung disease. These data show for the first time that PAR-1 signaling plays a key role in experimentally induced lung injury, and they further identify PAR-1 as one of the critical receptors involved in orchestrating the interplay between coagulation, inflammation, and remodeling in response to tissue injury.
    American Journal Of Pathology 06/2005; 166(5):1353-65. DOI:10.1016/S0002-9440(10)62354-1 · 4.59 Impact Factor
Show more